

# **Increasing of new CA-MRSA infections detected in PLWH who engage in chemsex in Barcelona: An ambispective study**

Lorena DE LA MORA <sup>a</sup>, Cristina PITART <sup>b</sup>, Laura MORATA <sup>c</sup>, Ainoa UGARTE <sup>a</sup>, María MARTINEZ-REBOLLAR <sup>a</sup>, Elisa DE LAZZARI <sup>a</sup>, Andrea VERGARA <sup>b</sup>, Jordi BOSCH <sup>b</sup>, Ignasi Roca <sup>b</sup>, Maria Piquet <sup>b</sup>, Ana RODRIGUEZ <sup>a</sup>, Montserrat LAGUNO <sup>a</sup>, Juan AMBROSIONI <sup>a</sup>, Berta TORRES <sup>a</sup>, Ana GONZÁLEZ-CORDÓN <sup>a</sup>, Alexy INCIARTE <sup>a</sup>, Alberto FONCILLAS <sup>a</sup>, Josep RIERA <sup>d</sup>, Irene FUERTES <sup>d</sup>, Iván CHIVITE <sup>a</sup>, Esteban MARTINEZ <sup>a</sup>, José L. BLANCO <sup>a</sup>, Alex Soriano <sup>c</sup> and Josep MALLOLAS <sup>a</sup>

<sup>a</sup> HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV research group, University of Barcelona, Spain.

<sup>b</sup> Department of Clinical Microbiology, ISGlobal, Hospital Clínic—University of Barcelona, CIBERINF, Spain

<sup>c</sup> Department of Infectious Diseases, Hospital Clinic, IDIBAPS, CIBERINF, University of Barcelona, Spain

<sup>d</sup> Dermatology Service, Hospital Clinic, IDIBAPS, University of Barcelona Spain.

Correspondence to: Maria MARTINEZ-REBOLLAR. HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS AIDS and HIV research group, Barcelona University, Spain. Villarroel 170, 08036, Barcelona, Spain. Phone number: +34 983 227 55 74. Fax number: +34 93 4515424. Email: [rebollar@clinic.cat](mailto:rebollar@clinic.cat)

Lorena De La Mora and Cristina Pitart contributed equally to the study. Alex Soriano and Josep Mallolas contributed equally to the study as co-senior authors. Maria Martínez-Rebollar is the corresponding author.

**Table 2. Chemsex characterization**

<b>Sexual behaviors</b>		
<b>Sexual partners</b>		
<i>Median (IQR) [n]</i>		
Sexual partners, last 3 months (N=19)		12 (5; 21)
Sexual partners, last 12 months (N=5)		40 (20; 60)
<b>Sexual practices</b>		
		<b>n (%)</b>
Anal sex (N=23)	Unprotected	17 (74%)
	Protected	1 (4%)
	Sometimes	5 (22%)
Oral sex (N=25)	Unprotected	19 (76%)
	Protected	1 (4%)
	Sometimes	5 (20%)
Double penetration (N=11)	Unprotected	9 (82%)
	Sometimes protected	2 (18%)
Fisting (N=5)	Unprotected	4 (80%)
	Sometimes protected	1 (20%)
Sexual toys (N=8)	Unprotected	3 (38%)
	Protected	2 (25%)
	Sometimes protected	3 (38%)
	Shares sexual toys	6 (76%)
<b>Drug use characterization</b>		
<b>Drug</b>		
		<b>n (%)</b>
Cocaine (N=25)		3 (12%)
Ketamine (N=25)		3 (12%)
GHB/GBL (N=25)		23 (92%)
Methamphetamine (N=25)		24 (96%)
Mephedrone (N=25)		10 (40%)
Speed (N=25)		3 (12%)
MDMA (N=25)		4 (16%)
Alkyl nitrites (N=25)		12 (48%)
ED agents (N=25)		15 (60%)
Cannabis (N=25)		4 (16%)
<b>Route of drug administration</b>		
Oral (N=24)		19 (79%)
Inhaled (N=24)		21 (88%)
Snorted (N=24)		7 (29%)

Sublingual (N=24)	4 (17%)
Rectal (N=24)	3 (13%)
Endovenous or <i>slamming</i> (N=24)	12 (46%)
Sharing venipuncture material if slamming (N=12)	1 (8%)
Use of sterile materials if slamming (N=8)	8 (73%)
<b>Frequency of drug use</b>	
Every day (N=23)	6 (26%)
Every week (N=23)	11 (48%)
Every month (N=23)	5 (21%)
< 1 time per month (N=23)	3 (13%)
<b>Number of drugs used</b>	
1 drug (N=25)	2 (8%)
2 drugs (N=25)	15 (60%)
Polydrug use* (N=25)	8 (32%)

\* *consumption of ≥3 drugs*